Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Greece: Road to Recovery.
COVID-19
Greece
HPV
Switzerland
adolescents
routine vaccines
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
25 Jan 2023
25 Jan 2023
Historique:
received:
07
12
2022
revised:
06
01
2023
accepted:
18
01
2023
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
1
3
2023
Statut:
epublish
Résumé
The COVID-19 pandemic has caused significant disruptions to healthcare, including reduced administration of routinely recommended HPV vaccines in a number of European countries. Because the extent and trends of accumulated vaccine dose deficits may vary by country, decision-makers need country-specific information regarding vaccine deficits to plan effective catch-up initiatives. To address this knowledge gap in Switzerland and Greece, this study used a previously published COVID-19 recovery calculator and historical vaccine sales data to quantify the cumulative number of missed doses and the catch-up rate required to clear the deficit in Switzerland and Greece. The resultant cumulative deficit in HPV doses for Switzerland and Greece were 24.4% and 21.7%, respectively, of the total number of doses disseminated in 2019. To clear the dose deficit by December 2025, monthly vaccination rates must be increased by 6.3% and 6.0% compared to 2019 rates in Switzerland and Greece, respectively. This study demonstrates that administration rates of routine HPV vaccines decreased significantly among Swiss and Greek adolescents during the COVID-19 pandemic and that a sustained increase in vaccination rates is necessary to recover the HPV dose deficits identified and to prevent long-term public health consequences.
Identifiants
pubmed: 36851136
pii: vaccines11020258
doi: 10.3390/vaccines11020258
pmc: PMC9964352
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Merck Sharp & Dohme LLC
ID : N/A
Références
JAMA Pediatr. 2015 Apr;169(4):365-73
pubmed: 25706340
Lancet. 2009 Jul 25;374(9686):301-14
pubmed: 19586656
N Engl J Med. 2007 May 10;356(19):1928-43
pubmed: 17494926
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
Rev Saude Publica. 2020 Nov 09;54:115
pubmed: 33175029
Expert Rev Vaccines. 2020 Nov;19(11):1073-1083
pubmed: 33267673
Med Decis Making. 2013 Oct;33(7):920-36
pubmed: 23858015
Lancet Glob Health. 2022 Feb;10(2):e186-e194
pubmed: 34951973
Lancet Glob Health. 2020 Feb;8(2):e180-e190
pubmed: 31862245
Mol Oncol. 2021 Mar;15(3):770-778
pubmed: 33058497
BMJ Glob Health. 2021 Dec;6(12):
pubmed: 34857523
Pediatrics. 2006 Nov;118(5):e1287-92
pubmed: 17079529
Curr Med Res Opin. 2021 Dec;37(12):2077-2087
pubmed: 34538163
Public Health. 2020 Oct;187:136-139
pubmed: 32961466
Acta Paediatr. 2021 Sep;110(9):2559-2566
pubmed: 33973264
BMJ. 2020 Jun 16;369:m2392
pubmed: 32546575
Vaccine. 2015 Oct 26;33(43):5741-5746
pubmed: 26424607
Health Sci Rep. 2022 Feb 18;5(2):e00516
pubmed: 35224217
Vaccine. 2021 May 12;39(20):2731-2735
pubmed: 33875269
BMJ Open. 2018 May 17;8(5):e021006
pubmed: 29773702
Vaccine. 2022 Jun 9;40(26):3664-3669
pubmed: 35570078
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):999-1001
pubmed: 32734936
Front Public Health. 2022 Aug 01;10:907720
pubmed: 35979457
Vaccines (Basel). 2022 Jul 16;10(7):
pubmed: 35891297
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):591-593
pubmed: 32407298
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915976
Pediatrics. 2008 Jan;121 Suppl 1:S46-54
pubmed: 18174320